Hanmi Pharm, Genentech Sign $2.3 Billion Exclusive Licensing Agreement for Obesity Drug

MT Newswires Live

Yesterday

Hanmi Pharm (KRX:128940) signed an exclusive licensing agreement with Switzerland-based Roche Group member Genentech to develop, manufacture, and commercialize the former's obesity drug, the South Korean firm said in a Monday release.

The drug HM17321 (urocortin-2) is a novel metabolic treatment candidate for treating obesity and associated conditions such as type 2 diabetes and cardiovascular diseases, the release said.

Under the deal, Hanmi will receive an upfront payment of $190 million, with the total deal valued at $2.3 billion. In addition, the South Korean firm will be eligible to receive tiered royalties on future product sales after commercialization of the drug, it said.

Shares of Hanmi Pharm jumped 30% at market close.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2661278213"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2661278213\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2661278213?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-24 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661278213","market":"hk","top_or_hot":-1,"title":"Hanmi Pharm, Genentech Sign $2.3 Billion Exclusive Licensing Agreement for Obesity Drug","media":"MT Newswires Live","content":"<html><body><p> Hanmi Pharm (KRX:128940) signed an exclusive licensing agreement with Switzerland-based Roche Group member Genentech to develop, manufacture, and commercialize the former's obesity drug, the South Korean firm said in a Monday release.</p><p>The drug HM17321 (urocortin-2) is a novel metabolic treatment candidate for treating obesity and associated conditions such as type 2 diabetes and cardiovascular diseases, the release said.</p><p>Under the deal, Hanmi will receive an upfront payment of $190 million, with the total deal valued at $2.3 billion. In addition, the South Korean firm will be eligible to receive tiered royalties on future product sales after commercialization of the drug, it said.</p><p>Shares of Hanmi Pharm jumped 30% at market close.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanmi Pharm, Genentech Sign $2.3 Billion Exclusive Licensing Agreement for Obesity Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanmi Pharm, Genentech Sign $2.3 Billion Exclusive Licensing Agreement for Obesity Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-24 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hanmi Pharm (KRX:128940) signed an exclusive licensing agreement with Switzerland-based Roche Group member Genentech to develop, manufacture, and commercialize the former's obesity drug, the South Korean firm said in a Monday release.</p><p>The drug HM17321 (urocortin-2) is a novel metabolic treatment candidate for treating obesity and associated conditions such as type 2 diabetes and cardiovascular diseases, the release said.</p><p>Under the deal, Hanmi will receive an upfront payment of $190 million, with the total deal valued at $2.3 billion. In addition, the South Korean firm will be eligible to receive tiered royalties on future product sales after commercialization of the drug, it said.</p><p>Shares of Hanmi Pharm jumped 30% at market close.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2661278213","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2661278213","pubTimestamp":1787568482,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hanmi Pharm  signed an exclusive licensing agreement with Switzerland-based Roche Group member Genentech to develop, manufacture, and commercialize the former's obesity drug, the South Korean firm said in a Monday release.The drug HM17321  is a novel metabolic treatment candidate for treating obesity and associated conditions such as type 2 diabetes and cardiovascular diseases, the release said.Under the deal, Hanmi will receive an upfront payment of $190 million, with the total deal valued at $2.3 billion. In addition, the South Korean firm will be eligible to receive tiered royalties on future product sales after commercialization of the drug, it said.Shares of Hanmi Pharm jumped 30% at market close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","HAFC":"韩美金融"},"translate_title":"韩美制药与基因泰克签署23亿美元肥胖药物独家许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAFC":1.5},"content_text":"Hanmi Pharm (KRX:128940) signed an exclusive licensing agreement with Switzerland-based Roche Group member Genentech to develop, manufacture, and commercialize the former's obesity drug, the South Korean firm said in a Monday release.The drug HM17321 (urocortin-2) is a novel metabolic treatment candidate for treating obesity and associated conditions such as type 2 diabetes and cardiovascular diseases, the release said.Under the deal, Hanmi will receive an upfront payment of $190 million, with the total deal valued at $2.3 billion. In addition, the South Korean firm will be eligible to receive tiered royalties on future product sales after commercialization of the drug, it said.Shares of Hanmi Pharm jumped 30% at market close.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}